Part the First: Anti-amyloid Antibodies and Alzheimer’s Disease (AD).  A Cochrane review of monoclonal antibodies targeting amyloid plaques in AD has found that these drugs have little to no effect on cognitive function of AD patients.  Cochrane reviews are, to use one of the favorite tropes of the current administration, considered the “gold standard” of […]